News | June 03, 2009

Naviscan Licenses Biopsy-Guidance Accessory

June 2, 2009 - Naviscan Inc. has issued a nonexclusive licensing agreement with an undisclosed imaging company for intellectual property that enables Naviscan’s Stereo Navigator PEM-guided biopsy accessory to obtain emission data, locate the abnormal tissue and process the data to guide a biopsy needle.

This is the second licensing agreement based on Naviscan’s intellectual property portfolio, reinforces Naviscan’s leadership position in molecular breast imaging (MBI). The company is currently negotiating licensing agreements with other diagnostic imaging companies and expects these agreements to be signed as early as the third quarter of 2009.

The new licensing agreement covers the use of Stereo Navigator, a medical method and apparatus for the localization and biopsy of lesions. This patent enables PET scanners and gamma cameras to obtain emission data, locate the abnormal tissue and process the data to best guide a biopsy needle to acquire a sample of the abnormal tissue. The previous licensing agreement concerned a method and apparatus patent enabling the immobilization and compression of a body part for the purposes of collecting PET or gamma emission data in an effort to create a physiological image of the body part.

Naviscan currently has four other patents pending.

Naviscan was recently awarded Frost & Sullivan’s 2009 “Emerging Technology of the Year.”

For more information: www.naviscan.com

Related Content

News | Biopsy Systems | March 29, 2019
Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy...
FDA Clears Ion Endoluminal Lung Biopsy System
Technology | Interventional Radiology | February 20, 2019
The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...